Dr. L. Madison Michael to conduct first-in-human clinical trial for RevBio’s bone adhesive biomaterial

Semmes Murphey is thrilled to announce that Phase II of RevBio’s bone adhesive biomaterial clinical trial will take place at the clinic in Memphis! RevBio was recently awarded a $2.4 million grant from the National Institute of Neurological Disease and Stroke. The two-year, Phase II Small Business Innovation Research grant will allow the company to complete a clinical trial for its bone adhesive biomaterial called TETRANITE. Semmes Murphey physician Dr. L. Madison Michael will be the lead neurosurgeon for the trial at the clinic.

TETRANITE will be used for cranial flaps and enable bone fusion following craniotomy procedures. The adhesive will improve bone healing through revascularization of the flap and provide better cosmetic outcomes for patients. This advanced technique will also improve survival rates for patients who undergo brain surgery.

Learn more about this groundbreaking procedure in RevBio's official announcement. To speak to a Semmes Murphey physician about this new surgical procedure or a spinal condition, schedule an appointment with us today by calling 901-522-7700 or visiting our appointments page.